Results 181 to 190 of about 24,744 (229)
Some of the next articles are maybe not open access.
Thiazolidinediones and inflammation
Lupus, 2005Thiazolidinediones (TZDs) are selective ligands of peroxisome-proliferator-activated receptor g increasingly used in the treatment of type 2 diabetes. Both in vitro and in vivo studies provide evidence that TZDs have anti-inflammatory properties. TZDs inhibit macrophage activation and decrease inflammatory cytokine expression and release in macrophage
Agostino Consoli
exaly +4 more sources
Southern Medical Journal, 2002
Several new drugs have become available for the treatment of type 2 diabetes mellitus in the past few years, and among them the thiazolidinediones are probably the most promising and interesting. Their mechanism of action involves a reduction in insulin resistance while simultaneously improving some of the independent risk factors for cardiovascular ...
Fernando, Ovalle +1 more
+6 more sources
Several new drugs have become available for the treatment of type 2 diabetes mellitus in the past few years, and among them the thiazolidinediones are probably the most promising and interesting. Their mechanism of action involves a reduction in insulin resistance while simultaneously improving some of the independent risk factors for cardiovascular ...
Fernando, Ovalle +1 more
+6 more sources
Hepatotoxicity of the thiazolidinediones
Clinics in Liver Disease, 2003Troglitazone, the first of the thiazolidinediones, caused severe hepatotoxicity including liver failure in several patients. It appears, however, that the thiazolidinediones as a class are not as hepatotoxic as troglitazone. Comparative data at comparable dates of usage indicate that pioglitazone and rosiglitazone are not significant hepatotoxins. This
Keith G, Tolman, Jane, Chandramouli
openaire +2 more sources
Expert Opinion on Drug Safety, 2012
Thiazolidinediones (TZDs) initially showed great promise as unique receptor-mediated oral therapy for type 2 diabetes, but a host of serious side effects, primarily cardiovascular, have limited their utility. It is crucial at this point to perform a risk-benefit analysis to determine what role TZDs should play in our current treatment of type 2 ...
Jacqueline, Kung, Robert R, Henry
openaire +2 more sources
Thiazolidinediones (TZDs) initially showed great promise as unique receptor-mediated oral therapy for type 2 diabetes, but a host of serious side effects, primarily cardiovascular, have limited their utility. It is crucial at this point to perform a risk-benefit analysis to determine what role TZDs should play in our current treatment of type 2 ...
Jacqueline, Kung, Robert R, Henry
openaire +2 more sources
The Lancet, 2000
Thiazolidinediones, which are being developed for the treatment of insulin resistance and type 2 diabetes mellitus, bind and activate peroxisome proliferator-activated receptor gamma, a nuclear receptor that regulates the expression of several genes involved in metabolism.
Schoonjans, Kristina, Auwerx, Johan
openaire +3 more sources
Thiazolidinediones, which are being developed for the treatment of insulin resistance and type 2 diabetes mellitus, bind and activate peroxisome proliferator-activated receptor gamma, a nuclear receptor that regulates the expression of several genes involved in metabolism.
Schoonjans, Kristina, Auwerx, Johan
openaire +3 more sources
Endocrinology and Metabolism Clinics of North America, 1997
The thiazolidinediones are a unique class of compounds that exert direct effects on the mechanisms of insulin resistance and result in improved insulin action and reduced hyperinsulinemia. Troglitazone is the first of these compounds to be approved for use in humans and has the potential not only to reduce glycemia and insulin requirements in type II ...
openaire +2 more sources
The thiazolidinediones are a unique class of compounds that exert direct effects on the mechanisms of insulin resistance and result in improved insulin action and reduced hyperinsulinemia. Troglitazone is the first of these compounds to be approved for use in humans and has the potential not only to reduce glycemia and insulin requirements in type II ...
openaire +2 more sources
The safety of thiazolidinediones
Expert Opinion on Drug Safety, 2011The prevalence of type 2 diabetes mellitus (T2DM) has reached epidemic proportions. Many new therapies have emerged, including thiazolidinediones (TZDs), selective agonists of PPAR-γ, now used as both primary and add-on therapies. Given that T2DM is a lifetime disease, there is a need for assurance that new drugs are both safe and effective.
openaire +2 more sources
Hepatotoxicity of thiazolidinediones
Expert Opinion on Drug Safety, 2003Thiazolidinediones are insulin sensitisers now widely used for the treatment of Type 2 diabetes mellitus. The initial marketed drug in this class, troglitazone, was removed from the market worldwide after approximately 3 years of use due to rare but severe hepatotoxicity, which sometimes resulted in liver failure leading to the need for liver ...
openaire +2 more sources
Thiazolidinediones in dermatology
International Journal of Dermatology, 2007AbstractThiazolidinediones, also known as glitazones, represent a relatively new class of medication used for glycemic control in patients with type II diabetes mellitus. These drugs interact with the peroxisome proliferator‐activated receptor γ, a member of the nuclear receptor superfamily, which in turn heterodimerizes with retinoid X receptors to ...
openaire +2 more sources
Nihon rinsho. Japanese journal of clinical medicine, 2007
Sunder Mudaliar, Robert Henry
+7 more sources
Sunder Mudaliar, Robert Henry
+7 more sources